A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Reliant Pharmaceuticals
  • Most Recent Events

    • 15 Nov 2010 Results published online in the Journal of the American Medical Association.
    • 15 Nov 2010 Study findings were presented at the American Heart Association's Scientific Sessions and published online in the Journal of the American Medical Association, according to a GlaxoSmithKline media release.
    • 30 Aug 2010 Actual end date changed from Feb 2010 to Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top